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Summary
 
Major histocompatibility complex (MHC) class I antigens are constitutively expressed yet highly
induced by interferon (IFN) during inflammation. We found that not only IFN-induced but
also normal basal expression of MHC I required IFN receptors and signal transducer and acti-
vator of transcription (STAT)1, providing genetic evidence for continuous IFN signaling. Sur-
prisingly, an IFN-independent requirement for STAT1 was also found, specifically in T lym-
phocytes, where MHC class I expression was not fully accounted for by IFN signaling. This
IFN-independent pathway maintained tyrosine phosphorylation of STAT1 in T but not B
lymphocytes even in the absence of IFN receptors. Interestingly, interleukin (IL)-7 selectively
activated STAT1 and induced MHC class I in mature T but not B cells. These loss of function
studies demonstrate an essential role of endogenous IFN and activated STAT1 for constitutive
MHC class I expression in normal mice and define IL-7–dependent but IFN-independent reg-
ulation of STAT1 restricted to T lymphocytes.
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M
 
HC class I antigens, which are cell surface glycopro-
teins composed of a heavy chain and a light chain
(
 
b
 
2-microglobulin [
 
b
 
2m]), are ubiquitously expressed on
most nucleated cells. The levels of MHC class I can be reg-
ulated by various cytokines, including IFNs and TNF-
 
a
 
,
and by mitogens such as LPS, phorbol esters, and Con A
(1). Expression of MHC class I is tightly regulated during
development (2–4) and differentiation (5) and is required
for immune recognition of virus infection and for T cell
development. Antigen presentation by MHC class I is essen-
tial for both the development and the effector function of
CD8
 
1
 
 CTLs. Differential expression of MHC class I on thy-
mic epithelial and dendritic cells influences both positive and
negative selection of immature thymocytes (6).
Expression of MHC class I genes is controlled by both
transcriptional and posttranslational mechanisms. Transcrip-
tional regulation of MHC class I heavy chain is controlled
through transcription factor binding sites in the promoters
of the MHC class I genes (7, 8). Conserved cis-acting ele-
ments include enhancer A, IFN consensus sequence (ICS),
 
1
 
and site 
 
a
 
. Enhancer A contains regions I and II recognized
by members of the retinoic acid receptor family (5) and the
nuclear factor (NF)-
 
k
 
B/Rel family (9), respectively. The
binding of NF-
 
k
 
B is essential for constitutive class I expres-
sion and for induction by mitogens and by cytokines such
as TNF (10). ICS contains an IFN-stimulated response ele-
ment that is the target site for transcription factors of the
IFN regulatory factor (IRF) family, such as IRF-1, IRF-2,
IRF-9 (ISGF3
 
g
 
 p48), and IRF-8 (ICS-binding protein),
and it mediates the induction of MHC class I expression by
IFNs. The interactions of different transcription factors at
enhancer A and ICS sites can achieve synergistic effects on
the regulation of MHC class I genes (11). MHC class II
transactivator (CIITA), a global regulator for MHC class II
molecules, is also involved in the constitutive and IFN-
 
g
 
–
induced expression of MHC class I genes through site 
 
a
 
(12, 13).
Two sets of molecules involved in antigen processing
and presentation are also essential for cell surface expression
of MHC class I molecules (14, 15). LMP2 and LMP7, two
subunits associated with the 20S proteasome, are required
for enhanced processing of cytosolic proteins into small
peptides (16). Mice lacking LMP2 and LMP7 are deficient
in presenting antigens and in MHC class I surface expres-
sion (17, 18). Transporter associated with antigen process-
ing (TAP)1 and TAP2 are transporter proteins that form
heterodimers and facilitate movement of peptides from the
cytosol into the lumen of the endoplasmic reticulum, where
 
1
 
Abbreviations used in this paper:
 
 BMT, bone marrow transplantation; DN,
double-negative; DP, double-positive; EMSA, electrophoretic mobility
gel shift; GFP, green fluorescent protein; ICS, IFN consensus sequence;
IRF, IFN regulatory factor; NF, nuclear factor; PML, promyelocytic leu-
kemia; SP, single-positive; STAT, signal transducer and activator of tran-
scription; TAP, transporter associated with antigen processing. 
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they are loaded into the groove of the MHC class I heavy
chain, and these transporters are also required for MHC
class I expression (19). For instance, RMA-S, a mutant cell
line lacking TAP2, is defective in the expression of MHC
class I on the cell surface owing to its rapid degradation in
the absence of peptide (20). MHC class I structural genes as
well as the processing machinery and some of the regula-
tory transcription factors are all induced by IFN during in-
flammation.
Induction of the MHC complex by type I and type II
IFN is abrogated in the absence of signal transducer and ac-
tivator of transcription (STAT)1 (21, 22), demonstrating
the absolute requirement of STAT1 for IFN-stimulated
transcriptional responses. As no STAT1 binding site was
found in the promoter of the MHC class I gene, the role of
STAT1 in IFN-
 
g
 
–mediated MHC class I induction is
likely to be indirect. Several transcription factors implicated
in MHC class I expression are themselves targets for STAT1,
such as IRF-1 and CIITA. However, during IFN-
 
a
 
/
 
b
 
 re-
sponses, STAT1 may directly induce class I gene expression
by forming the ISGF3 complex in conjunction with STAT2
and IRF-9, which in turn binds to the ICS of MHC class I
promoters (23). The fact that IFN-
 
b
 
 was capable of induc-
ing MHC class I expression in IRF-1
 
2
 
/
 
2
 
 fibroblasts sug-
gests that the binding of ISGF3 to the ICS is sufficient for
MHC class I induction (24).
JAK–STAT signaling, first characterized in the IFN sys-
tem, has been shown to be essential for many cytokine re-
sponses (25, 26). One of the surprises revealed by genetic
studies of STAT deficiency is the remarkable specificity of
individual STAT molecules for distinct cytokine signaling
systems (27) in spite of the more promiscuous activation
observed in cell culture. However, we have also explored
possible roles for STAT1 outside of inflammatory responses
to IFN. For instance, a role for STAT1 in response to fi-
broblast growth factor was detected during chondrocyte
development in organ cultures (28), and in this paper we
provide evidence that STAT1 is required for basal expres-
sion of MHC class I. Part of this requirement for STAT1 is
due to a constitutive rather than an inflammatory role for
IFN and demonstrates a steady-state requirement for IFN
in the absence of infection. Unexpectedly, we also observed
an IFN-independent and cell type–restricted role for STAT1
specifically in T but not B lymphocytes.
The cell type specificity of the IFN-independent STAT1
requirement corresponds to the responsiveness of cells to
IL-7. IL-7 is a cytokine that is essential for lymphoid devel-
opment (29–31), with its specific receptor IL-7R
 
a
 
 ex-
pressed on T and B lineage progenitors. In the thymus,
double-negative (DN) and single-positive (SP) cells but not
double-positive (DP) cells express IL-7R
 
a
 
, and the recep-
tor is expressed on peripheral T but not B lymphocytes. IL-7
signals through JAK1 and JAK3 and has been shown to ac-
tivate STAT5a and STAT5b (32) and possibly STAT1 (33),
and it promotes the survival of lymphoid cells, which is
particularly critical for thymic precursors (34). Recently,
IL-7 was also shown to induce immune recognition mole-
cules, including MHC class I, in acute myeloid leukemia
 
and lymphoid leukemia patients (35). Here, we show that
IL-7 also activates STAT1 in mature T lymphocytes, lead-
ing to increased expression of MHC class I.
 
Materials and Methods
 
Animals.
 
Generation of STAT1
 
2
 
/
 
2
 
 (36), IFN-
 
a
 
 receptor
(IFNAR)1
 
2
 
/
 
2
 
 (37), and IFN-
 
g
 
 receptor (IFNGR)1
 
2
 
/
 
2
 
 mice
 
 
 
(38)
has been described. IFNAR and IFNGR double-knockout mice
(AR
 
1
 
GR)
 
2
 
/
 
2
 
 were derived by interbreeding IFNAR
 
2
 
/
 
2
 
 and
IFNGR
 
2
 
/
 
2
 
 mice and screening for compound homozygous mu-
tant offspring. Strain backgrounds were either 129 or C57BL/6
(eighth backcross generation) and were compared with wild-type
mice of the same strain. Mice were housed under specific patho-
gen–free conditions, and all work with animals conformed to
guidelines approved by the Institutional Animal Care and Use
Committee of New York University School of Medicine.
 
Flow Cytometry.
 
Lymphocytes of thymi, spleens, and lymph
nodes were prepared from 6–8-wk-old mice. Triple staining for
surface markers was performed by incubating 
 
z
 
10
 
6
 
 cells first with
M1/42.3 (TIB-126; American Type Culture Collection), a rat
mAb that recognizes a framework epitope common to mouse
MHC class I, followed by staining cells with FITC-conjugated
anti–rat IgG (Caltag Labs.). Cells were subsequently incubated
with anti–CD4-TC (tricolor) and anti–CD8-PE or anti–B220-PE
antibodies (Caltag Labs.) in the presence of normal rat serum to
block cross-reactions. Stained cells were washed two times with
cold staining buffer (0.2% BSA and 0.1% sodium azide in PBS)
and fixed with 1% paraformaldehyde in staining buffer, followed
by FACS™ analysis. Additional surface markers were analyzed
using anti–H-2K
 
b
 
–PE (PharMingen) and anti–I-A
 
b
 
–biotin, anti–
IgM-biotin, and streptavidin–allophycocyanin (Caltag Labs.). For
comparing MHC class I induction in response to IFN-
 
g
 
 and IL-7,
selected lymphocyte populations were incubated in the presence
or absence of cytokine for 48 h, followed by FACS™ analysis.
Mean channel shift was the average increase in mean fluorescence
intensity (39) and varied 
 
,
 
10% for three separate experiments.
 
Northern Blot Analysis.
 
20 
 
m
 
g of total RNA prepared from
splenocytes or thymocytes using Trizol reagent (Life Technolo-
gies) was resolved on 1.5% denaturing agarose gels and transferred to
nitrocellulose membranes. cDNA probes were derived from splenic
RNA by reverse transcriptase–PCR. The primer sets for ampli-
fying different genes were as follows: LMP2, forward primer,
5
 
9
 
-ATGCTGCGGGCAGGAGCACCTACCGC-3
 
9 
 
and reverse
primer, 5
 
9
 
-TCACTCATCGTAGAATTTTGGCAGCTC-3
 
9
 
;
LMP7, forward primer, 5
 
9
 
-ATGGCGTTACTGGATCTGTGCG-
GTGC-3
 
9 
 
and reverse primer, 5
 
9
 
-TCACAGAGCGGCCTCTC-
CGTACTTGTA-3
 
9
 
; TAP1, forward primer, 5
 
9
 
-AGTGTCTC-
GGGAATGCTGCTGAAGGTG-3
 
9
 
 and reverse primer, 5
 
9
 
-AGT-
GTGCAGTCCAGAGGCCTTGTCGTCTG-3
 
9
 
; 
 
b
 
-actin, forward
primer, 5
 
9
 
-GTGGGGCGCCCCAGGCACCA-3
 
9
 
 and reverse
primer, 5
 
9
 
-CTCCTTATTGTCACGCACGATTTC-3
 
9
 
; MHC I,
forward primer, 5
 
9
 
-GCACAGATTCCCCAAAGG-3
 
9
 
 and reverse
primer, 5
 
9
 
-ATCTCAGGGTGAGGGGCTCA-3
 
9
 
; 
 
b
 
2m, for-
ward primer, 5
 
9
 
-GTGACCCTAGTCTTTCTGGTG-3
 
9
 
 and re-
verse primer, 5
 
9
 
-TGAATCTTCAGAGCATCATG-3
 
9
 
; IRF-1,
forward primer, 5
 
9
 
-TCCATGGAAGCACGCTGCTA-3
 
9
 
 and
reverse primer, 5
 
9
 
-AGACTGCTGCTGACGACACA-3
 
9
 
.
The amplified DNA fragments were purified and labeled using
RadPrime DNA labeling kits (Life Technologies). Hybridization,
washing, and stripping of the nitrocellulose membrane followed
standard procedures (40). To quantify specific signals, membranes
were exposed to PhosphorImager screens (Molecular Dynamics) 
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and analyzed according to the manufacturer’s instructions. Quan-
titative measurements were normalized to values for actin.
 
Retroviral Transduction of Bone Marrow Cells and Bone Marrow
Transplantation.
 
Production of retrovirus was as described (41).
A murine stem cell virus vector expressing humanized green flu-
orescent protein (GFP; a gift of Dr. W. Pear, University of Penn-
sylvania, Philadelphia, PA) was transfected into the Phoenix
packaging cell line (a gift of Dr. G.P. Nolan, Stanford, CA), and
culture supernatant was used as viral stock. Transduction of bone
marrow cells with retrovirus was as described (42). In brief,
C57BL/6 wild-type or STAT1
 
2
 
/
 
2
 
 mice were treated with 150
mg/kg 5-fluorouracil (Sigma Chemical Co.) 6 d before harvest.
Bone marrow cells were harvested and incubated on Retro-
nectin
 
TM
 
 (Takara-Shuzo) coated dishes containing bone marrow
transfer medium (IL-3, 6 ng/ml; stem cell factor, 10 ng/ml; and
IL-6, 10 ng/ml, all from PeproTech, Inc., and 20% FBS in
RPMI 1640) and 1 ml of recombinant virus for 48 h. Cultures
were supplemented with 1 ml of fresh virus after the first 24 h.
1.6 million bone marrow cells were injected intravenously into
lethally irradiated (900 rads) wild-type or STAT1
 
2
 
/
 
2
 
 recipients.
Mononuclear cells recovered from peripheral blood of recipient
mice were analyzed by double staining with anti–H-2K
 
b
 
–PE and
anti–TCR-allophycocyanin or IgM-allophycocyanin after gating
for GFP fluorescence to score donor-derived lymphocytes.
 
Separation of T and B Lymphocytes and Analysis of Nuclear Extracts.
 
Freshly isolated splenocytes were incubated with rat anti-B220 at
0.2 
 
m
 
g/10
 
6
 
 cells for 30 min at 4
 
8
 
C. Antibody-bound cells were
washed twice with 1
 
3
 
 PBS and incubated with anti–rat anti-
body–coated M450 Dynabeads (Dynal) for 30 min at 4
 
8
 
C on a
mixer. B cells were collected using a magnet after three washes
with 1
 
3
 
 PBS containing 0.2% BSA. Nuclear extracts prepared
from positively selected B cells and negatively selected T cells
were resolved in 7% SDS-PAGE, followed by Western blot anal-
ysis as described (43). The antibodies used for immunoblots were
anti–phosphotyrosyl-STAT1 (Zymed Labs.) and anti–STAT1
COOH terminus (STAT1C; a gift from Dr. C. Schindler, Colum-
bia University, New York, NY). Purity of selected cell popula-
tions was verified by flow cytometry. B cell fractions were typi-
cally 
 
.
 
95% pure; T cell fractions were 
 
.
 
80% pure.
 
Electrophoretic Mobility Gel Shift.
 
Nuclear extracts prepared from
Dynabead-selected T or B cells, which were left untreated or
treated with human recombinant IL-7 (10 ng/ml; StemCell) or
IFN-
 
g
 
 (100 U/ml; Boehringer Mannheim) for 30 min, were an-
alyzed using a 
 
32
 
P-labeled probe containing a high-affinity GAS
sequence (44) in the presence or absence of anti-STAT1C anti-
body as described (43).
 
Results
 
Decreased Surface Expression of MHC Class I on STAT1
 
2
 
/
 
2
 
Lymphocytes.
 
Type I and type II IFNs are known modula-
tors of MHC antigen expression during inflammation and
viral infection (45). Because STAT1 is a signal transducer
shared by both types of IFNs, we examined the expression
of MHC antigens on freshly isolated lymphocytes from
wild-type or STAT1
 
2
 
/
 
2
 
 mice with antibody to either
MHC class I (M1/42.3, an mAb recognizing a framework
epitope of MHC class I) or class II (I-A
 
b
 
). Cells from
STAT1
 
2
 
/
 
2
 
 mice housed under pathogen-free conditions
showed a two- to threefold reduction of surface MHC class I
compared with lymphocytes from wild-type mice (Fig. 1 A).
The expression of MHC class II, however, was comparable
on lymphocytes of both genotypes (Fig. 1 B), even though
both class I and class II expression can be induced by IFN,
and both show an absolute requirement for STAT1 for in-
duction (21). Reduced expression and absence of induction
of MHC class I was not due to a global defect, however,
because class I expression was induced in response to mito-
genic stimulation of both B and T splenocytes devoid of
STAT1 (data not shown), reflecting an intact NF-
 
k
 
B path-
way (46–48).
 
Reduced Expression of mRNA for MHC Class I Genes and
Antigen Processing and Presentation Molecules in STAT1
 
2
 
/
 
2
 
Lymphocytes.
 
To explore the mechanisms underlying the
reduction of cell surface expression of MHC class I in the
absence of STAT1, we examined the levels of MHC class I
heavy chain and light chain (
 
b
 
2m) mRNA by Northern
hybridization. To assess the potential role of constitutive IFN
in this regulation, we included lymphocytes lacking recep-
tors for either IFN-
 
a
 
 or IFN-
 
g
 
 derived from IFNAR
 
2
 
/
 
2
 
or IFNGR
 
2
 
/
 
2
 
 mice. As shown in Fig. 2 A, MHC class I
heavy chain and 
 
b
 
2m mRNA levels were reduced signifi-
cantly in both thymi and spleens of STAT1
 
2
 
/
 
2
 
 mice. Quan-
titation of the mRNA levels of MHC class I heavy and
light chains after normalization with the values for actin
showed 
 
z
 
50–70% reduction compared with wild-type lev-
els. The mRNA levels of MHC class I heavy chain and, to a
lesser degree, light chain were also decreased in the thymi
of IFNAR
 
2
 
/
 
2
 
 and IFNGR2/2 mice, showing that at least
part of the regulation of basal class I expression requires an
intact IFN signaling pathway. Similar reductions were also
observed in splenocytes. To study the possible role of other
transcription factors in reduced MHC class I expression, we
examined the level of IRF-1 mRNA, which is a STAT1
target and has been shown to modulate the levels of both
MHC class I heavy and light chain in response to IFN-g
(49, 50). IRF-1 mRNA levels were decreased substantially
(30–50%) in spleens and thymi of STAT12/2 mice (Fig. 2 A)
and to a lesser extent in lymphocytes from IFNAR2/2 and
IFNGR2/2 mice. These results suggest that IFNs, operat-
ing through STAT1 and possibly IRF-1, are required to
Figure 1. Reduced surface expression of MHC class I, but not class II,
on STAT12/2 lymphocytes. Freshly isolated splenocytes prepared from
wild-type (thin lines) or STAT12/2 mice (bold lines) were stained with
antibodies against MHC class I (A) or class II (anti–I-Ab) (B), followed by
FACS™ analysis. Dotted/dashed lines represent staining with secondary
antibody alone.1454 Constitutive Regulation of MHC Class I by STAT1
maintain full basal mRNA levels of MHC class I heavy and
light chains. Interestingly, class I heavy and light chain
mRNA expression was much higher in spleen than thymus
(Fig. 2 A). Similarly increased cell surface class I protein
levels were observed in peripheral relative to immature
lymphocytes, suggesting a developmental upregulation of
class I molecules during maturation.
As antigen processing and presentation molecules are also
critical for surface expression of the MHC class I complex,
we measured the mRNA levels of these accessory molecules.
As shown in Fig. 2 B, TAP1, LMP2, and LMP7 expression
was reduced to z35% of wild-type levels in splenocytes
and thymocytes from STAT12/2 mice. Smaller reductions
of TAP1, LMP2, and LMP7 mRNA levels were seen in
thymus and spleen of IFNAR2/2 and IFNGR2/2 mice.
These results showed that all of the MHC class I complex
and related genes examined were regulated by STAT1 and
that the regulation was at least partially due to constitutive
IFN signaling. In all cases, loss of STAT1 produced a more
severe reduction in MHC class I and accessory molecules
than did loss of a single IFN receptor, suggesting that the
phenotype of STAT12/2 mice was due to either the addi-
tive effect of loss of both type I and type II IFN receptors
or to an IFN-independent mechanism.
A nuclear protein recently implicated in the control of
MHC class I gene expression and antigen processing is the
promyelocytic leukemia (PML) protooncogene (51). PML
mRNA expression was reduced approximately twofold in
spleen cells from STAT12/2 mice (Fig. 2 C). Because this
protein may act as a master regulator of MHC class I cell
surface expression that functions downstream of STAT1, its
reduction in STAT12/2 cells may contribute to reduced
MHC class I cell surface levels. Interestingly, like class I
heavy and light chain genes, PML was also expressed at
higher levels in spleen relative to thymus, indicating its po-
tential involvement in the developmental switch in class I
expression in lymphocytes.
STAT1 Regulates Constitutive MHC Class I Expression on
Lymphocytes by a Cell-intrinsic Mechanism. Reduced expres-
sion of MHC class I molecules observed in the absence of
STAT1 could be due to either a cell-intrinsic role for
STAT1 in lymphocytes, e.g., downstream of a cytokine re-
ceptor, or to a more global role elsewhere in the animal,
e.g., regulating production of a secreted cytokine that ulti-
mately targets lymphocytes. To determine if the reduction
of MHC class I was a primary, cell-autonomous defect, we
performed bone marrow transplantation (BMT). Bone mar-
row cells from either wild-type or STAT12/2 mice were
used to reconstitute either STAT11/1 or STAT2/2 animals
that had been lethally irradiated. To distinguish donor-
derived lymphocytes from residual endogenous cells of the
recipient mice, donor cells were infected with a retrovirus
expressing GFP. The levels of MHC class I on mature pe-
ripheral blood lymphocytes were monitored 6 wk after BMT
by staining with antibodies against MHC class I plus TCR
for mature T cells or plus IgM for mature B cells and gating
on GFP-positive lymphocytes.
Four types of transplants were performed: STAT11/1
cells transferred into STAT11/1 or STAT12/2 mice and
STAT12/2 cells transferred into STAT11/1 or STAT12/2
mice. Wild-type and STAT12/2 bone marrow was capable of
reconstituting both mature T and B lymphocytes in mice
of both genotypes (Fig. 3). STAT12/2 bone marrow was
somewhat less efficient at reconstituting mature T lym-
phocytes than wild-type donors, although the cause of this
deficiency is unclear. Nonetheless, on both subsets of lym-
phocytes, MHC class I expression levels reflected the geno-
type of the donor rather than that of the recipient.
STAT11/1 cells transferred into STAT12/2 hosts acquired
an MHC class I phenotype similar to that of wild-type cells
(Fig. 3, A and B, second rows from top), whereas STAT12/2
cells transferred to STAT11/1 hosts maintained their re-
duced levels of MHC class I (Fig. 3, third rows from top).
Autologous transplants also maintained the level of MHC
Figure 2. Genes for MHC class I
antigen processing and presentation
are regulated by STAT1. (A) Re-
duced expression of heavy and light
chain mRNA in the absence of
STAT1. 20 mg of total RNA pre-
pared from lymphocytes of thymi or
spleens of wild-type, STAT12/2,
IFNAR2/2, or IFNGR2/2 mice
were hybridized with 32P-labeled
probes specific for MHC class I
heavy chain, light chain (b2m), and
IRF-1. (B) Reduced constitutive
mRNA for antigen processing and
presentation–related molecules. Abun-
dance of TAP1, LMP2, LMP7, and
actin was measured as described for
A. (C) PML is regulated by STAT1
and is differentially expressed in thy-
mus and spleen. Abundance of PML
and glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) mRNA was
analyzed by Northern hybridization.1455 Lee et al.
class I appropriate for their genotype (Fig. 3, first and fourth
rows from top). These results demonstrated that basal ex-
pression of MHC class I on T and B lymphocytes is regu-
lated by a cell-intrinsic process that depends on the STAT1
status of the cell itself, independent of the environment in
which it matures.
STAT1-dependent but IFN-independent Regulation of MHC
Class I Expression in Mature T Lymphocytes. The greater re-
duction of class I heavy and light chain mRNA in STAT12/2
cells relative to IFN receptor mutants (Fig. 2) suggested
that STAT1 may be important even in the absence of IFN.
To further examine the role of constitutive IFN signaling
in MHC expression patterns on different subsets of lym-
phocytes, we compared MHC class I antigen levels on
lymphocytes from mice devoid of IFN signaling by com-
bined loss of receptors for both IFN-a and IFN-g (Fig. 4).
As noted above, higher levels of MHC class I expression
were detected on lymphocytes from peripheral organs
than on thymocytes. Different subsets of T lymphocytes
also displayed different levels of class I. CD41CD81 DP
thymocytes expressed very limited amounts of surface
MHC class I compared with CD42CD82 DN or CD42
CD81 and CD41CD82 SP thymocytes (Table I). In periph-
eral organs, the levels of MHC class I on both CD4 and
CD8 T lymphocytes were further elevated compared with
those of SP thymocytes.
In spite of the differential expression of MHC class I on
different lymphocyte populations, when the levels of MHC
Figure 3. Expression of MHC class I is cell autono-
mous. Peripheral blood lymphocytes prepared after BMT
were double stained with anti–H-2Kb–PE and anti–TCR-
allophycocyanin (A) or anti–IgM-allophycocyanin (B), fol-
lowed by FACS™ analysis gating on GFP-positive lym-
phocytes. Mean fluorescence intensity (MFI) is the average
MHC class I intensity of GFP–TCR or GFP–IgM DP
lymphocytes (circled regions) from three to four chimeric
mice. The relative percentages of TCR1 or IgM1 cells
among GFP1 lymphocytes are shown.1456 Constitutive Regulation of MHC Class I by STAT1
class I were compared between STAT12/2 and wild-type
animals, all subsets of lymphocytes, whether from thymus,
spleen, or lymph nodes, showed reduced expression of
MHC class I in the absence of STAT1 (Table I and Fig. 4).
Whereas DP and DN thymocytes and B lymphocytes from
spleen and lymph nodes showed 40–50% reduction of MHC
class I, SP thymocytes (CD42CD81 and CD41CD82) and
peripheral T lymphocytes (both CD4 and CD8) showed a
more pronounced reduction of MHC class I expression
(only 16–26% of wild-type levels). MHC class I expression
was also reduced on other cells types, including monocytes,
macrophages, NK cells, and mouse embryonic fibroblasts
(data not shown), suggesting that STAT1 is generally required
for maintaining constitutive levels of MHC I expression.
RNA expression studies (Fig. 3) suggested that class I
levels regulated by STAT1 were at least partially indepen-
dent of the presence of either IFN receptor. This observa-
tion left open the possibility that the more severe defect
observed in the absence of STAT1 could be due to the
combined loss of IFN-a and IFN-g signaling. We there-
fore tested class I protein levels in the absence of both IFN-a
and IFN-g receptors using cells from (AR1GR)2/2 mice.
To exclude the possibility that any variation in MHC class I
expression was due to differences in genetic background,
wild-type, STAT12/2, IFNAR2/2, and (AR1GR)2/2 mice
were maintained on the 129 (H-2b) strain background.
A similar reduced level of MHC class I was observed on
B cells of both spleens and lymph nodes from (AR1GR)2/2
and STAT12/2 mice (Table I and Fig. 4 B). Therefore, the
STAT1 requirement in B cells is likely to be entirely down-
Figure 4. Reduced surface expression of MHC
class I antigens in different subsets of STAT12/2
lymphocytes. Freshly isolated lymphocytes from
thymi (A) or lymph nodes (B) of wild-type (dashed
lines), STAT12/2 (bold lines), or (AR1GR)2/2
(thin lines) mice were triple stained with CD4–
TC, CD8–PE, and MHC class I–FITC, followed
by FACS™ analysis. CD42CD82 lymphocytes
from lymph nodes were regarded as B cells.
Table I. Mean Fluorescence Intensity of MHC Class I in Different Subsets of Lymphocytes
Thymocytes Splenocytes Lymph nodes
CD4282 CD4281 CD4181 CD4182 B CD8 CD4 B CD8 CD4
Wild type 974 706 69 531 974 1,562 1,368 1,097 1,709 1,520
STAT12/2 374 186 30 107 585 396 379 632 358 252
IFNAR2/2 689 614 52 463 663 1,273 926 703 1,230 904
IFNGR2/2 530 538 40 346 599 874 644 665 1,099 664
(AR1GR)2/2 464 489 43 321 597 793 577 586 883 5371457 Lee et al.
stream of IFN signaling. Surprisingly, however, SP thymo-
cytes and CD4 and CD8 T lymphocytes from STAT12/2
mice displayed a more pronounced reduction of MHC
class I (z50%) than those from (AR1GR)2/2 mice. There-
fore, STAT1 was required for the expression of MHC class I
antigens on maturing and peripheral T lymphocytes even
in the absence of any IFN signaling.
IFN-independent Phosphorylation and Nuclear Translocation
of STAT1 in Resting T but not B Lymphocytes. The preced-
ing results showed that endogenous IFNs were present and
functional in normal animals but also indicated that STAT1-
dependent gene expression could be independent of IFN
signaling. These results prompted us to test the tyrosine
phosphorylation and nuclear accumulation of STAT1, an
indication of its activation by cytokines. Nuclear extracts
prepared from freshly isolated splenocytes of wild-type,
STAT12/2, and (AR1GR)2/2 mice were subjected to
immunoblot with antibody specific for tyrosine-phosphor-
ylated STAT1. As shown in Fig. 5 A, top panel, phospho-
STAT1a and phospho-STAT1b were indeed detected in
nuclear extracts of wild-type resting splenocytes, presum-
ably indicative of the action of IFN. Strikingly, a lower but
still significant level of phospho-STAT1 was also detected
in the (AR1GR)2/2 splenocytes. Whereas the decreased
activation of STAT1 in (AR1GR)2/2 lymphocytes rela-
tive to wild-type cells was presumably due to the loss of IFN
responsiveness, the residual phospho-STAT1 in (AR1GR)2/2
lymphocytes must result from an IFN-independent mecha-
nism. These results demonstrate that both IFN-dependent
and -independent pathways contributed to the basal activa-
tion of STAT1 in lymphocytes.
MHC class I expression was differentially regulated in T
and B cells; specifically, STAT1-mediated expression in B
cells was entirely IFN dependent, yet both IFN-dependent
and -independent pathways were involved in STAT1-
mediated expression in T cells (Fig. 4). Therefore, we
tested whether the regulation of basal activation of STAT1
also varied in these two subsets of lymphocytes. Nuclear
extracts from isolated splenic T and B lymphocytes of wild-
type and (AR1GR)2/2 mice were analyzed for phospho-
STAT1. As shown in Fig. 5 B, activated STAT1a and
STAT1b were detected in both T and B lymphocytes of
wild-type mice. In contrast to wild-type lymphocytes,
phospho-STAT1 levels were undetectable in B cells from
(AR1GR)2/2 mice but could still be detected in T cells.
Therefore, STAT1 activity in B cells was entirely depen-
dent on IFN signaling, whereas both IFN-dependent and
-independent pathways mediated STAT1 activation selec-
tively in T cells. This dual mode of STAT1 activation was
not limited to splenic T lymphocytes; basal activation of
STAT1 was also present in (AR1GR)2/2 thymocytes (Fig.
5 B). This pattern of STAT1 activation mirrors the regula-
tion we found for MHC class I gene expression.
Selective Activation of STAT1 by IL-7 in Mature T but not B
Lymphocytes. The previous results defined an IFN-inde-
pendent activation of STAT1 in T but not B cells. We rea-
soned that factors involved in selective activation of STAT1
might be cytokines preferentially acting on thymic and
splenic T cells but not on mature B cells. One such candi-
date is IL-7, whose receptor is expressed on both T and B
lineage progenitors (52–54) but not on DP thymocytes or
mature peripheral B lymphocytes (55). STAT1 phosphory-
lation in freshly isolated splenocytes was blocked by the ki-
nase inhibitor staurosporine (data not shown), suggestive of
the action of a cytokine signaling pathway. Therefore, we
first examined whether IL-7 could activate STAT1 in lym-
phocytes. STAT1 activation was significantly enhanced af-
ter either IL-7 or IFN-g treatment of splenic T cells from
wild-type mice (Fig. 6 A, top panel). A comparable level of
activated STAT1 was present in T cells of (AR1GR)2/2
mice after IL-7 treatment but not after IFN-g treatment,
due to the absence of IFN-g receptors. STAT1 was also ac-
tivated in thymocytes of wild-type and (AR1GR)2/2
mice in response to IL-7 (data not shown). In marked con-
trast to T cells, no activation of STAT1 was observed in
IL-7–treated B lymphocytes, although IFN-g was still ca-
pable of activating STAT1 in B cells of wild-type though
not (AR1GR)2/2 mice (Fig. 6 A, bottom panel).
To further confirm the selective response to IL-7 in T
versus B cells, electrophoretic mobility gel shift (EMSA)
was performed using nuclear extracts from purified lym-
phocyte populations. Whereas IL-7 treatment induced the
formation of two complexes in T cells from wild-type mice,
IFN-g only activated a complex with mobility correspond-
Figure 5. (A) Basal phosphorylation of STAT1 in sple-
nocytes of wild-type and (AR1GR)2/2 mice. Nuclear ex-
tracts prepared from 1.5 3 107 freshly isolated splenocytes
of wild-type, STAT12/2, and (AR1GR)2/2 mice were
resolved in 7% SDS-PAGE and transferred to nitrocellu-
lose membrane, followed by immunoblot with anti–phos-
photyrosyl-STAT1 (STAT1-PTyr) antibody (top panel). The
blot was then stripped and reblotted with anti-STAT1C
antibody that only recognizes full length STAT1a (bottom
panel). (B) Basal phosphorylation of STAT1 in B but not
T cells completely depends on IFN signaling. Western blot
as described for A was performed using nuclear extracts
prepared from 107 splenic T or B cells or thymocytes of
wild-type and (AR1GR)2/2 mice.1458 Constitutive Regulation of MHC Class I by STAT1
ing to the lower band of the IL-7–activated complexes (Fig.
6 B). Antibodies to STAT1 (Fig. 6 B, fourth lane from left)
and STAT5 (not shown) identified these complexes as
STAT1 (Fig. 6 B, bottom panel) and STAT5 (Fig. 6 B, top
panel). However, whereas a STAT1 complex was activated
by IFN-g in B cells from wild-type mice, no complexes
were activated in response to IL-7 in these cells (Fig. 6 B,
bottom panel). IL-2 and IL-4, other cytokines capable of
activating STAT5, failed to activate STAT1 (data not shown).
Therefore, IL-7 selectively activated STAT1 in T but not
B cells and functioned independently from IFN, consistent
with the pattern previously observed for MHC class I ex-
pression.
IL-7–dependent Induction of MHC Class I Expression on T
Cells. As STAT1 is essential for MHC class I expression,
the differential activation of STAT1 in T and B cells by IL-7
prompted us to examine IL-7–dependent modulation of
class I expression. Splenocytes and thymocytes of wild-
type, (AR1GR)2/2, and STAT12/2 mice were treated
with IL-7 or IFN-g for 48 h, and induction of class I pro-
tein expression was followed by FACS™ analysis (Table
II). Whereas IFN-g induced MHC class I expression on
both T and B cells of wild-type mice, IL-7 selectively in-
duced class I expression only on T cells (Table II, top). This
IL-7–dependent induction of MHC class I was not second-
ary to IFN signaling, as a comparable induction of MHC
class I expression occurred on T cells from (AR1GR)2/2
mice. IL-7 also induced class I on DN and SP thymocytes
from wild-type mice but not on DP thymocytes that lack
IL-7Ra (Table II, bottom). In contrast, neither IL-7 nor
IFN-g caused significant class I induction on cells defi-
cient in STAT1, similar to the lack of effect of IL-7 on
receptor-negative B cells. Analogous results were obtained
with IL-7R–positive pre-B cell lines derived from bone
marrow; MHC class I was induced in response to IL-7 on
wild-type but not STAT12/2 cells (data not shown). Taken
together, these results demonstrate that STAT1 is capable
of mediating MHC class I induction in response to IL-7,
and we conclude that STAT1 and IL-7 contribute to the
basal level of MHC class I on mature T lymphocytes.
Discussion
We have demonstrated a role for constitutive IFN sig-
naling in the absence of inflammation for homeostatic gene
regulation in normal lymphocytes. This genetic and bio-
Figure 6. Differential activation of STAT1 by IL-7
in T and B cells. (A) Nuclear extracts prepared from se-
lected T (top panel) or B (bottom panel) cells were left
untreated or treated with IL-7 or IFN-g for 30 min,
followed by electrophoresis and immunoblot with
anti–phosphotyrosyl-STAT1 (STAT1-PTyr) as described
in the Fig. 5 legend. Basal phosphorylation of STAT1
was readily detected upon longer exposure (not shown).
(B) EMSA was performed with nuclear extracts pre-
pared as described for A in the presence or absence of
antibody to STAT1C.
Table II. Mean Channel Shift of MHC Class I Expression
Treatment
Splenocytes:
Wild type (AR1GR)2/2 STAT12/2
TB TB TB
IFN-g 76 379 0 0 6 0
IL-7 103 27 101 12 18 7
Treatment
Thymocytes:
Wild type STAT12/2
CD4182 CD4281 CD4282 CD4181 CD4182 CD4281 CD4282 CD4181
IFN-g 97 52 69 60 1 0 1 1
IL-7 60 50 30 1 9 7 8 2
Splenocytes and thymocytes were treated with IFN-g (100 U/ml) or IL-7 (10 ng/ml) for 48 h.1459 Lee et al.
chemical analysis has also revealed underlying differences in
the regulation of MHC class I expression in T and B cells.
Moreover, these data uncovered a novel IFN-independent
but IL-7–dependent STAT1 activity that operates selectively
in T lymphocytes. A model for these different modes of
regulation is illustrated in Fig. 7. In both T and B cells, con-
stitutive IFN signaling activates STAT1 to maintain MHC
class I gene expression either directly in combination with
STAT2 and IRF-9 or possibly indirectly through its down-
stream target, IRF-1. In addition, both cell types have IFN-
independent mechanisms for regulation of class I levels. In
T cells, an IL-7–dependent but IFN-independent mecha-
nism activates STAT1 phosphorylation, and this STAT1-
dependent signaling is necessary for full class I expression.
In B cells, the IFN-independent mechanism is also STAT1
independent, possibly acting through the B cell–specific
protein CIITA that has been shown to modulate MHC
class I gene expression (12, 13).
The role of IL-7 has been mainly characterized during
lymphoid development, where it is required to prevent ap-
optosis in lymphoid precursors (34) and to serve as a cofac-
tor for V(D)J recombination in both T and B lymphocytes
(53, 54). These actions of IL-7 depend on JAK1, (56) JAK3
(57), and STAT5, though the requirement for STAT1 signal-
ing is less clear (58, 59). Here we provide evidence that IL-7
is also important in mature T cells for maintenance of consti-
tutive expression of MHC class I through activated STAT1.
However, the role of STAT1 activation in the upregula-
tion of MHC class I in response to IL-7 is likely indirect,
possibly through IRF-1, a downstream target of STAT1.
STAT1 can be activated in response to cytokines and growth
factors other than IFN, at least in cell culture, but initial ev-
idence from in vivo studies largely failed to support these
alternative activators, suggesting instead that STAT1 was
dedicated to IFN signaling (21, 36, 60). Recent evidence
has suggested that fibroblast growth factor also functions
through STAT1 in developing chondrocytes, at least in or-
gan culture (28). IL-7–mediated STAT1 activation demon-
strates a novel role for STAT1 outside the scope of IFN.
For B cells, no phospho-STAT1 accumulated in the ab-
sence of IFN signaling, and MHC class I levels were equiva-
lent between STAT12/2 and (AR1GR)2/2 mice. A STAT1-
independent mechanism was operative for maintaining
basal expression (Fig. 7), possibly through B cell–specific
proteins such as CIITA, first characterized as regulators of
MHC class II (12, 13). Indeed, overexpression of CIITA in
human G3A cells, which are defective in CIITA, enhances
the expression of MHC class I. It is likely that the action of
CIITA compensates for the loss of IFN and STAT1 signal-
ing in B cells derived from (AR1GR)2/2 and STAT12/2
mice, allowing them to retain modest expression of MHC
class I. The unchanged patterns of surface MHC class II
(Fig. 1 B) and equal levels of CIITA mRNA in all mouse
strains tested (data not shown) suggest that CIITA-depen-
dent pathways are intact in the absence of STAT1, although
their responsiveness to IFN is lost. Interestingly, expression
of MHC class I on peripheral macrophages from STAT12/2
and (AR1GR)2/2 mice were similar (data not shown).
Macrophages also express CIITA and display high constitu-
tive levels of MHC class II, consistent with a class I pheno-
type similar to that of B cells. CIITA is unable to perform
this basal function in most tissues, as its expression outside
the antigen presentation system is dependent on IFN in-
duction. The important role of B lymphocytes and mac-
rophages as APCs may explain why they have evolved in-
dependent mechanisms to maintain MHC expression.
We have demonstrated that basal activation of STAT1 in
resting lymphocytes relies on the action of at least two dif-
ferent cytokines, namely IFN and probably IL-7. Although
both IFN and IL-7 are involved in activating STAT1 in T
lymphocytes, this action is entirely IFN dependent in B
lymphocytes. Similarly, STAT1 basal phosphorylation is
maintained by both IFN and IL-7 in SP and DN thy-
mocytes but not in DP thymocytes that lack IL-7Ra and
display very low levels of MHC class I. One of the func-
tions of the constitutively activated STAT1 is to maintain
MHC class I expression, although it is also likely that other
targets exist as well. Interestingly, it has recently been
shown that constitutively phosphorylated STAT1 accumu-
lates in lung epithelium of asthmatic patients in the absence
of IFN (61), suggesting that the tight regulation of STAT1
phosphorylation is important for normal physiology. Al-
Figure 7. Differential regulation of constitutive MHC
class I expression in T and B cells. Two pathways contrib-
ute to STAT1 activation that are essential for basal MHC
class I expression in T cells. The first pathway is IFN de-
pendent, whereas the second does not require IFN recep-
tors and may depend on a cytokine, such as IL-7, to main-
tain MHC class I expression. In B cells, STAT1 activation
is entirely dependent on IFN, whereas additional B cell–
specific transcription factors, such as CIITA, contribute to
the maintenance of MHC class I expression in a STAT1-
independent manner.1460 Constitutive Regulation of MHC Class I by STAT1
though it has been known that IFN is responsible for in-
creased class I expression during immune responses, we pro-
vide evidence for the continuous presence of IFNs in vivo
in the absence of overt infection in the maintenance of
basal levels of expression. The presence of endogenous
IFNs in vivo has been suggested from low levels of IFN
mRNA detected in various human organs (62), but the
presence or significance of IFN protein in the absence of an
inflammatory response has been less clear. Here we provide
genetic and biochemical evidence for IFNs exerting a con-
stitutive biological response. The source of basal IFN has
not been determined, and we cannot exclude a role for sub-
clinical infection or possibly normal intestinal flora. How-
ever, we suggest that basal IFN production, whether spon-
taneously produced or induced by common environmental
stimuli, contributes to normal immune homeostasis. Con-
sistent with this notion, gene-targeted loss of the inhibitor
SOCS1 produced severe pathology (63) that appeared to be
entirely due to unopposed IFN signaling (64a), again sug-
gesting the presence of biologically active IFN in the ab-
sence of overt infection. Likewise, the transcriptional re-
pressor IRF-2 appears to be essential to inhibit basal IFN
responses, and ablation of IRF-2 leads to IFN-dependent
pathology (64). These findings suggest a novel function for
IFN as a homeostatic cytokine in addition to its role as an
inflammatory mediator. Constitutive IFN signaling is re-
quired for beneficial responses, such as maintenance of MHC
class I expression and perhaps priming a state of readiness
for combating viral infection (65), whereas the less benign
effects required only during inflammation are held in check
by negative regulators, such as IRF-2 and SOCS1. It seems
likely that other cytokines would have similar dual roles in
both homeostatic and stress situations.
The mechanisms of developmental control of MHC class
I expression are still largely uncharacterized. We show that
expression of MHC class I is downregulated during the
transition from DN to DP thymocytes, followed by reex-
pression on SP thymocytes. It was further enhanced when
SP thymocytes matured to peripheral CD4 and CD8 T lym-
phocytes. Relative changes of MHC class I levels from DN
to DP and from DP to SP thymocytes or SP thymocytes to
peripheral T lymphocytes were comparable in wild-type
and IFN receptor and STAT1 mutant mice (Table I), sug-
gesting that neither IFN nor STAT1 is responsible for this
developmental control. Interestingly, PML expression, a pos-
sible regulator of MHC class I downstream of STAT1 (51),
was also higher in spleen than thymus; therefore, it may be
one of the factors underlying developmental control.
IRF-1 has also been shown to affect MHC class I expres-
sion, inducing mRNA levels for heavy chain, LMP2, and
TAP1 (66, 67). IRF-1 is a STAT1 target and was substan-
tially reduced in STAT12/2 mice and, therefore, is likely
one of the downstream mediators of STAT1 in this process.
However, IRF-1 is not essential for regulation of MHC
class I expression, at least in response to IFN-a/b, as MHC
class I expression was still induced in IRF-12/2 cells, pre-
sumably through the action of the ISGF3 complex (24).
Nonetheless, STAT12/2 and IRF-12/2 mice do not dis-
play identical phenotypes. Despite the decreased expression
of MHC class I on STAT12/2 cells, we have not observed
any abnormalities in CD8 development (data not shown),
suggesting that the levels of MHC class I on thymic epithe-
lium were still sufficient to rescue CD81 SP cells during
positive selection. In contrast, IRF-12/2 mice show an in-
creased ratio of CD4/CD8 cells due to an intrinsic require-
ment of IRF-1 for CD8 cell development (66).
One of the main functions of MHC class I is to facilitate
CD8 T lymphocyte–mediated cell cytotoxicity during in-
tracellular infection by viruses or bacteria. However, these
pathogens have evolved many strategies to escape from im-
mune responses by targeting the class I complex (68). For
example, cytomegalovirus and adenovirus are able to retain
MHC class I molecules in the endoplasmic reticulum or
Golgi complex through a retrieval signal in the cytoplasmic
tails of their viral proteins (69–71). HIV Nef protein modi-
fies the endocytic machinery to downmodulate surface ex-
pression of MHC class I (72). Recently, JAK–STAT signal-
ing was also shown to be disrupted during viral infection,
resulting in suppression of MHC induction by IFN-g (73,
74). The multiple modes of regulation of class I genes in B
cells and other APCs may provide a backup system for the
host during viral infection. When IFN signaling is targeted
by viruses, the professional APCs would be less sensitive to
the loss of IFN responsiveness in MHC class I regulation by
relying on STAT1-independent pathways. Indeed, STAT12/2
mice displayed comparable virus clearance compared with
wild-type mice after influenza virus infection (75). In vitro
CTL activity against autologous targets after infection with
influenza virus was also indistinguishable in STAT12/2 and
wild-type mice (data not shown).
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